CÜNEYT ÖZDEN, İsa GÜNAY, Tağmaç DEREN, Süleyman BULUT, Suha KOPARAL, Ali MEMİŞ

Effect of doxazosin on prostatic resistive index in patients with benign prostate hyperplasia

Amaç: Son yıllarda yapılan birkaç çalışmada benign prostat hiperplazili (BPH) hastaların power doppler ultrasonografi (USG) ile tespit edilen prostatik rezistif indekslerinde artış tespit edilmiştir. Bu çalışmada BPH’lı hastalarda doksazosin tedavisinin prostatik rezistif indeks üzerine etkisi değerlendirildi. Gereç ve Yöntemler: Çalışmaya alt üriner sistem semptomları nedeniyle BPH düşünülen 40 hasta alındı. Tüm hastalara 6 ay boyunca günde 8 mg doksazosin tedavisi verildi. Tedavi öncesi ve sonrası hastaların uluslararası semptom skorları (IPSS), maksimal akım hızları (Qmax), total prostat volümleri (TPV) ve power doppler USG ile tespit edilen prostatik rezistif indeksleri karşılaştırıldı. Bulgular: Hastaların ortalama yaşı 60.2±2 yıl, IPSS 20.3±4.5 ve Qmax 11.3 ±3.0 m/sn idi. Tedavi öncesi hastaların prostatik rezistive indeksi ile TPV ve IPSS arasında pozitif (sırasıyla, r=0.37 p=0.02 ve r=0.40 p=0.017), Qmax arasında negatif korelasyon tespit edildi (r=-0.38 p=0.021).Tedavi sonrası hastaların IPSS ve Qmax değerlerinde anlamlı derecede iyileşme mevcuttu (sırasıyla,7.9±5.3 ve 16.8±5.8, p

Benign prostat hiperplazili hastalarda doksazosinin prostatik rezistif indeks üzerine etkisi

Objective: In recent years several studies revealed that prostatic resistive index (RI) was increased on power Doppler imaging (PDI) in patients with benign prostate hyperplasia (BPH). In the present study we aimed to evaluate the effect of Doxazosin on prostatic RI in BPH patients. Materials and Methods: Forty BPH patients with lower urinary tract symptoms included in this study. All patients received 8mg Doxazosin daily for six months. International prostatic symptom scores (IPSS), maximal urine flow rates (Qmax), total prostate volumes and prostatic RI determination with PDI were compared before and after the treatment. Results: The mean age, IPSS and Qmax of the patients was 60.2±2 years, 20.3±4.5 and 11.3±3.0 mL/s respectively. There was a positive correlation between prostatic RI, total prostate volume and IPSS before the treatment (r=0.37 p=0.02 and r=0.40 p=0.017, respectively). On the other hand there was a negative correlation between prostatic RI and Qmax values (r= -0.38 p=0.021). There was a significant improvement in IPSS scores and Qmax values after the treatment (7.9±5.3 and 16.8±5.8 mL/s respectively, p<0.05). It was demonstrated that prostatic RI of the patients significantly decreased when compared to pretreatment levels (0.74±0.06 and 0.69±0.05 respectively, p<0.05). Conclusion: Our data demonstrated that Doxazosin treatment significantly decreased prostatic RI of the patients with BPH. We believe that prostatic RI could be a useful parameter for the follow-up of patients receiving medical treatment with BPH.

PDF

___

1) Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-479.
2) Holtgrewe HL. Economic issues and the management of benign prostatic hyperplasia. Urology 1995; 46 (supp l):23-25.
3) Kumar VL, Dewan S. Alpha adrenergic blockers in the treatment of benign hyperplasia of the prostate. Int Urol Nephrol 2000; 32: 67-71.
4) Schulman CC. Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment. Urology 2003; 62 (Suppl 1):24-33.
5) Schwinn DA, Roehrborn CG. Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol 2008;15:193-199.
6) Pool JL, Kirby RS. Clinical significance of alpha1- adrenoceptor selectivity in the management of benign prostatic hyperplasia. Int Urol Nephrol 2001; 33: 407-412.
7) Scarpa RM. Lower urinary tract symptoms: what are the implications for the patients? Eur Urol 2001; 40 (Suppl 4):12-20.
8) Porru D, Madeddu G, Campus G, Montisci I, Scarpa RM, Usai E. Evaluation of morbidity of multi-channel pressure-flow studies. Neurourol Urodyn. 1999; 18(6):647-652.
9) Kortmann BB, Sonke GS, D'ancona FC, Floratos DL, Debruyne FM, De La Rosette JJ. The tolerability of urodynamic studies and flexible cysto-urethroscopy used in the assessment of men with lower urinary tract symptoms. BJU Int 1999; 84: 449-453.
10) Tsuru N, Kurita Y, Suzuki K, Fujita K. Resistance index in benign prostatic hyperplasia using power Doppler imaging and clinical outcomes after transurethral vaporization of the prostate. Int J Urol 2005;12: 264-269.
11) Hayami S, Ushiyama T, Kurita Y, Kageyama S, Suzuki K, Fujita K. The value of power Doppler imaging to predict the histologic components of benign prostatic hyperplasia. Prostate 2002; 53: 168-174.
12) Tsuru N, Kurita Y, Masuda H, Suzuki K, Fujita K. Role of Doppler ultrasound and resistive index in benign prostatic hypertrophy. Int J Urol 2002; 9: 427-430.
13) Kojima M, Watanabe H, Watanabe M, Okihara K, Naya Y, Ukimura O. Preliminary results of power Doppler imaging in benign prostatic hyperplasia. Ultrasound Med Biol 1997; 23: 1305-1309.
14) Ozdemir H, Onur R, Bozgeyik Z, Orhan I, Ogras MS, Ogur E. Measuring resistance index in patients with BPH and lower urinary tract symptoms. J Clin Ultrasound 2005; 33:176-180.
15) Kojima M, Ochiai A, Naya Y, Okihara K, Ukimura O, Miki T. Doppler resistive index in benign prostatic hyperplasia: correlation with ultrasonic appearance of the prostate and infravesical obstruction. Eur Urol. 2000;37: 436-442.
16) Rubin JM, Adler RS. Power Doppler expands standard color capability. Diagn Imaging (San Franc) 1993; 15: 66-69.
17) Rubin JM, Bude RO, Carson PL, Bree RL, Adler RS. Power Doppler US: a potentially useful alternative to mean frequencybased color Doppler US. Radiology 1994; 190: 853-856.
18) Andersen M, Dahlstrand C, Høye K. Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia. Eur Urol 2000; 38: 400-409.
19) Kirby RS, Andersen M, Gratzke P, Dahlstrand C, Høye K. A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. BJU Int 2001; 87: 192-200.
20) MacDiarmid SA, Emery RT, Ferguson SF, McGuirt-Franklin R, McIntyre WJ, Johnson DE. A randomized double-blind study assessing 4 versus 8 mg. doxazosin for benign prostatic hyperplasia. J Urol 1999; 162: 1629-1632.
21) Shapiro E, Hartanto V, Lepor H. The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate 1992; 21: 297-307.
22) Zlota A, Sattar AA, Wespes E, Noel JC, Schulman CC. Is one single prostate biopsy helpful for choosing a medical treatment of benign prostatic hyperplasia? A quantitative computerized morphometric study. Urology 1996; 47: 329-334.